fbpx Skip to main content

Member's Profile

Phathom Pharmaceuticals, Inc.

100 Campus Dr Ste 102
Florham Park,   New Jersey
United States
Membership Info
Membership Type: Industry
Membership Since: 2019
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Phathom Pharmaceuticals, Inc.
Biotech Company
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI diseases. The company has the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in over 30 years.
Related News
No related news posted by this Member